These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 11838826)

  • 1. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.
    Cohen LG; Biederman J
    J Child Adolesc Psychopharmacol; 2001; 11(4):435-40. PubMed ID: 11838826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study.
    Cavallaro R; Cocchi F; Angelone SM; Lattuada E; Smeraldi E
    J Clin Psychiatry; 2004 Feb; 65(2):187-90. PubMed ID: 15003071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
    Tollin SR
    J Endocrinol Invest; 2000 Dec; 23(11):765-70. PubMed ID: 11194712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Risperidone-induced symptomatic hyperprolactinemia in youth with schizophrenia: efficacy and tolerability of cabergoline treatment].
    Pollice R; Di Giovambattista E; Tomassini A; Di Pucchio A; Mazza M; Di Michele V; Roncone R; Casacchia M
    Clin Ter; 2007; 158(2):121-6. PubMed ID: 17566512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabergoline-induced psychotic exacerbation in schizophrenic patients.
    Chang SC; Chen CH; Lu ML
    Gen Hosp Psychiatry; 2008; 30(4):378-80. PubMed ID: 18585544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiopulmonary complications of ergot-derivative dopamine agonists.
    Rack MJ; Baran AS; Richert AC; Roffwarg HP
    J Clin Psychiatry; 2004 Oct; 65(10):1429-30; author reply 1430. PubMed ID: 15491249
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
    Kalkavoura CS; Michopoulos I; Arvanitakis P; Theodoropoulou P; Dimopoulou K; Tzebelikos E; Lykouras L
    Exp Clin Psychopharmacol; 2013 Aug; 21(4):332-41. PubMed ID: 23834553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
    Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics.
    Coronas R; Cobo J; Giménez-Palop O; Ortega E; Márquez M
    Curr Drug Saf; 2012 Apr; 7(2):92-8. PubMed ID: 22873493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence of hyperprolactinemia and continuation of ovarian acyclicity in captive African elephants (Loxodonta africana) treated with cabergoline.
    Morfeld KA; Ball RL; Brown JL
    J Zoo Wildl Med; 2014 Sep; 45(3):569-76. PubMed ID: 25314824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
    Chen CK; Huang YS; Ree SC; Hsiao CC
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline.
    Moro M; Inada Y; Kojima M; Miyata H; Komatsu H; Torii R
    Eur J Pharmacol; 1999 Feb; 368(1):57-66. PubMed ID: 10096770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemia.
    Lissoni P; Vaghi M; Pescia S; Rovelli F; Ardizzola A; Valtulina F; Malugani F; Gardani G; Tancini G
    J Biol Regul Homeost Agents; 2004; 18(3-4):291-4. PubMed ID: 15786695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment.
    Masi G; Cosenza A; Mucci M
    J Child Adolesc Psychopharmacol; 2001; 11(4):389-94. PubMed ID: 11838821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone.
    Kinon BJ; Gilmore JA; Liu H; Halbreich UM
    Psychoneuroendocrinology; 2003 Apr; 28 Suppl 2():55-68. PubMed ID: 12650681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.
    Calarge CA; Ellingrod VL; Acion L; Miller DD; Moline J; Tansey MJ; Schlechte JA
    Pharmacogenet Genomics; 2009 May; 19(5):373-82. PubMed ID: 19339912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone.
    Roke Y; Buitelaar JK; Boot AM; Tenback D; van Harten PN
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):432-9. PubMed ID: 23234586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders.
    Hellings JA; Zarcone JR; Valdovinos MG; Reese RM; Gaughan E; Schroeder SR
    J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):885-92. PubMed ID: 16379508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.